Montpellier University Hospital
Montpellier, France
NCT Number: NCT05528809
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities, whose physiopathology remains largely unknown. Quantification and characterization of epithelial and endothelial circulants in Gougerot-Sjögren's syndrome could reflect the intensity of the epithelial aggression, and thus possibly constitute a biomarker.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Montpellier, France
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities.
The criteria for classification of the disease include dry syndrome, positive salivary gland biopsy and detection of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti-Sjögren's-syndrome-related antigen B (anti-SSB) antibodies. The presence of antibodies is thus important for the diagnosis but not essential, because in some patients the salivary gland biopsy is positive and the antibodies are absent. Therefore, the identification of new biomarkers could be very useful to confirm the diagnosis of primary Gougerot-Sjögren's syndrome and to identify subgroups of patients.
The pathophysiology of the disease remains largely unknown. Currently, primary Gougerot-Sjögren's syndrome is thought to originate from inflammation of the epithelial tissue of the salivary glands. However, it is currently unknown whether this autoimmune epithelitis is accompanied by a contingent of circulating epithelial cells, the characterization of which might be accessible by liquid biopsy.
So far, the circulating epithelial cells that have been identified have been identified in the context of cancer: in this case they are called circulating tumor cells. Their detection during primary Gougerot-Sjögren's syndrome could reflect the intensity of epithelial aggression, and thus possibly constitute a biomarker.
In other connectivities, data on circulating cells have already been published. In systemic scleroderma, another connectivitis affecting mainly middle-aged women, circulating progenitor cells have already been detected and are thought to have the capacity to differentiate into endothelial cells, thus playing a potentially important role in the pathophysiology of the disease.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A blood sampling will be performed during the inclusion visit (day 0).
Time frame: day 0
Rate of patients with at least 1 circulating epithelial cell in the peripheral blood
Time frame: day 0
Time frame: day 0
Time frame: day 0
University Hospital, Montpellier
Other
Acronym: CIRCEE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00025818
Arthritis, Arthritis, Rheumatoid
La Jolla, California, United States
View Trial DetailsNCT00001330
Autoimmune Diseases, Connective Tissue Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07115745
Arthritis, Arthritis, Rheumatoid
Boston, Massachusetts, United States
View Trial DetailsNCT07284797
Arthritis, Arthritis, Rheumatoid
Melbourne, Australia
View Trial Details